AELIS.PA Aelis Farma SA
- Market cap
- EUR 13.9M
- P/E
- -
- P/B
- 6.01x
- ROE
- -417.2%
- Dividend yield
- -
- Fundamental score
- 1.0/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is AELIS.PA undervalued?
Graham numberThe Graham number of Aelis Farma SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aelis Farma SA fundamental analysis
3 of 11 checks passedROE 0/2
The stock's ROE indicates a negative return (-144.4%) on shareholders' equity, suggesting poor financial performance.
ROA 0/2
The stock's ROA (-36.61%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.
PBV 0/2
The stock's elevated P/BV ratio (8.02x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.
DER 2/2
The stock has a minimal amount of debt (19%) relative to its ownership, showcasing a strong financial position and lower risk for investors.
Revenue Growth 0/2
Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.
Net Profit Growth 0/2
The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.
Assets Growth 1/2
This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.
Graham Number 0/1
The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.
Dividend Growth 0/2
The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.
Dividend 0/2
No dividends from the company in the past three years raises doubts about its profitability for shareholders.
Buffet Intrinsic Value 1/1
Warren Buffett's formula suggests that the company's stock is undervalued (17), making it an appealing investment prospect with its intrinsic value surpassing the current market price.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Aelis Farma SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aelis Farma SA
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company owns a pipeline of pharmacological inhibitors, including AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; AEF0217, a drug candidate, which is in phase 1/2 clinical trials to treat cognitive deficits observ…
Full company profileAelis Farma SA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aelis Farma SA annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 85.5K | 40.0K | 8.85K | 1.14M | 9.08M | 3.81M | 9.05M | 2.68M | 2.08M | 1.80M |
| Gross Profit | -2.17M | -2.86M | -3.13M | 1.11M | 9.08M | 3.81M | 9.05M | 2.68M | -279K | -11.8M |
| Operating Income | -1.99M | -2.63M | -2.99M | -4.05M | 2.55M | -8.53M | -6.46M | -7.74M | -8.28M | -12.6M |
| EBITDA | -1.99M | -3.48M | -4.51M | -3.57M | 844K | -16.2M | -6.35M | -7.18M | -8.00M | -12.4M |
| Net Income | -1.00M | -2.73M | -3.17M | -2.09M | 574K | -14.3M | -5.08M | -7.46M | -6.43M | -9.65M |
| EPS | -0.10 | -0.28 | -0.33 | -0.22 | 0.06 | -1.21 | -0.39 | -0.54 | -0.47 | -0.70 |
| Balance Sheet | ||||||||||
| Total Assets | 6.29M | 6.30M | 7.22M | 7.00M | 28.3M | 39.2M | 26.3M | 19.7M | 12.0M | 8.44M |
| Total Liabilities | 4.60M | 3.92M | 6.02M | 7.71M | 27.4M | 19.4M | 13.1M | 9.59M | 7.61M | 6.12M |
| Shareholders' Equity | 1.68M | 2.39M | 1.20M | -710K | 899K | 19.8M | 13.2M | 10.1M | 4.44M | 2.31M |
| Cash & Short-term Investments | 4.57M | 5.12M | 5.77M | 4.54M | 24.7M | 34.4M | 20.2M | 14.1M | 8.21M | 6.62M |
| Total Debt | 2.23M | 3.08M | 4.65M | 6.11M | 6.41M | 3.82M | 4.04M | 6.25M | 6.60M | 4.38M |
| Cash Flow | ||||||||||
| Operating Cash Flow | - | -3.55M | -2.89M | -2.48M | 19.0M | -13.1M | -12.6M | -11.8M | -5.38M | -7.99M |
| Capital Expenditure | 0.00 | 18.0K | 36.0K | 35.0K | 213K | 137K | 88.0K | 190K | 4.00K | 8.00K |
| Free Cash Flow | - | -3.57M | -2.92M | -2.51M | 18.8M | -13.2M | -12.7M | -11.7M | -5.39M | -8.00M |
| Ratios | ||||||||||
| ROE | -59.6% | -114.5% | -263.4% | - | 63.8% | -72.2% | -38.5% | -73.7% | -144.9% | -417.2% |
| ROA | -16.0% | -43.3% | -43.9% | -29.8% | 2.0% | -36.4% | -19.3% | -37.8% | -53.4% | -114.4% |
| Net Profit Margin | -1,173.2% | -6,834.7% | -35,826.5% | -183.5% | 6.3% | -375.1% | -56.1% | -278.4% | -308.7% | -537.2% |
| Debt to Equity | 1.33x | 1.29x | 3.86x | - | 7.13x | 0.19x | 0.31x | 0.62x | 1.49x | 1.89x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aelis Farma SA dividends
Aelis Farma SA has not paid dividends in the last 9 fiscal years.
Who owns Aelis Farma SA
- Insiders 36.44%
- Institutions 26.79%
- Public & others 36.77%
- Shares outstanding 13.6M
- Free float 4.07M
Aelis Farma SA company profile
- Company name
- Aelis Farma SA
- Ticker
- AELIS.PA
- ISIN
- FR0014007ZB4
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Fiscal year end
- December
- Address
- 1 rue Lafaurie de Monbadon, Bordeaux, France, 33000
- Phone
- 33 5 54 54 23 27
- Website
- aelisfarma.com
About Aelis Farma SA
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company owns a pipeline of pharmacological inhibitors, including AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; AEF0217, a drug candidate, which is in phase 1/2 clinical trials to treat cognitive deficits observed in down syndrome; and CB1-SSi, a new molecular entities to treat other CB1-dependent diseases, including several orphan diseases. Aelis Farma SA was incorporated in 2013 and is headquartered in Bordeaux, France.
Aelis Farma SA management
2- Dr. Pier Vincenzo Piazza M.D., Ph.D.CEO & Director · born 1961
- Stephanie MonlezunChief Operating Officer